Clinical Trial: Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma

U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07789522) titled 'Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma' on Aug. 24.

Brief Summary: This is a prospective, single-arm, single-center interventional study designed to evaluate the safety and efficacy of Elra-Isa-VR in patients with newly diagnosed ultra-high-risk multiple myeloma.

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma (MM)

Intervention: DRUG: anti-BCMA/CD3 bispecific antibody

Anti-BCMA/CD3 bispecific antibody (Elranatamab) will be administered via a subcutaneous injection (SC).

Recruitment Status: NOT_YET_RECRUITING

Sponso...